date,title,source
Oct-18-18,Verastem Oncology Announces Executive Leadership Appointments and Changes,Business Wire
Oct-18-18,"A Stock to be ""Aware of"" for Liver Cancer Awareness Month",ACCESSWIRE
Oct-24-18,"New Research Coverage Highlights Zoetis, TripAdvisor, The Gap, Unit, WestRock, and Verastem  Consolidated Revenues, Company Growth, and Expectations for 2018",GlobeNewswire
Oct-30-18,What's in Store for Verastem (VSTM) This Earnings Season?,Zacks
Nov-01-18,Cannabis and Biotech Firms Making Investors Boatloads,ACCESSWIRE
Nov-01-18,Verastem Oncology Announces Data Presentations at the American Society of Hematology 2018 Annual Meeting,Business Wire
Nov-05-18,Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),Business Wire
Nov-06-18,Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancers 33rd Annual Meeting,Business Wire
Nov-07-18,Verastem Oncology Reports Third Quarter 2018 Financial Results,Business Wire
Nov-07-18,Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma,Business Wire
Nov-29-18,Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?,Zacks
Dec-03-18,Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting,Business Wire
Dec-03-18,"New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Dec-04-18,Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting,Business Wire
Dec-19-18,Verastem Oncology Announces First Recipient of the Care Differently Award for Excellence in Patient Support and Education,Business Wire
Dec-20-18,"Have Insiders Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares This Year?",Simply Wall St.
Jan-03-19,Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress,Business Wire
Jan-03-19,Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference,Business Wire
Jan-04-19,"The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO",Benzinga
Jan-04-19,"New Research: Key Drivers of Growth for The Blackstone Group, Barnes & Noble, Verastem, Littelfuse, Essendant, and Anworth Mortgage Asset  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Jan-07-19,Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),Business Wire
Jan-09-19,4 Healthcare Stocks Looking To Set January Highs,ACCESSWIRE
Jan-11-19,Here's Why Verastem Tumbled 34.1% in December,Motley Fool
Jan-30-19,2 Small-Cap Biotech Stocks That Are on My Radar,TheStreet.com
Feb-04-19,Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),Business Wire
Feb-14-19,Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology,Business Wire
Feb-20-19,CORRECTING and REPLACING Verastem Oncology Announces Key Management Appointments,Business Wire
Feb-21-19,Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference,Business Wire
Feb-22-19,"Investor Expectations to Drive Momentum within Verastem, Molson Coors Brewing, SL Green Realty, UnitedHealth Group, TechTarget, and Icahn Enterprises  Discovering Underlying Factors of Influence",GlobeNewswire
Feb-26-19,"Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019",Business Wire
Mar-01-19,Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),Business Wire
Mar-04-19,Verastem Oncology Presents Phase 3 DUO Data Evaluating COPIKTRA (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy,Business Wire
